WebNational Center for Biotechnology Information WebJan 1, 2024 · Routine blood screening in the blood bank during these studies revealed uniformly positive results from the indirect antiglobulin test (IAT) in daratumumab-treated patients.16, 17 The IAT, also known as indirect Coombs test, is often performed to detect red blood cell (RBC) alloantibodies in plasma for compatibility before a RBC transfusion.
Blood Transfusion Management and Transfusion-Related …
WebMar 7, 2024 · Daratumumab injection (generic name: daratumumab) was approved by Food and Drug Administration (FDA) in the United States in 2015 and China in 2024 for the treatment of recurrent or refractory multiple myeloma (RRMM). WebDec 27, 2024 · Summary Daratumumab, a human IgG1κ monoclonal antibody targeting CD38, is used to treat multiple myeloma. We describe successful treatment with daratumumab in a case of treatment … dan newlin injury attorneys contact
Daratumumab: a first-in-class CD38 monoclonal antibody for the ...
WebDaratumumab binds to CD38 on red blood cells (RBCs) and results in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 … WebMar 1, 2024 · During preclinical development, daratumumab was specifically selected for its ability to mediate complement-dependent cytotoxicity (CDC). 9 It is has also been shown to kill target cells via antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and FCγR-mediated cross-linking–induced apoptosis. 6 … WebJan 27, 2024 · Treatment of multiple myeloma patients with daratumumab, a novel anti‐CD38 MoAb, resulted in false‐positive indirect antiglobulin tests (IATs) for all patients for 2 to 6 months after infusion, which precluded the correct identification of irregular blood group antibodies for patients requiring blood transfusion. 124 dan newlin locations